WVE insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 98% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 11 officers and directors who sold. 13 are left out

Left out: Ken Takanashi, Chandra Vargeese, Gregory Verdine, Paul Bolno, Kyle Moran, Erik Ingelsson, Christopher Wright, Heidi Wagner, Mark Corrigan, Aik Tan, Christian Henry, Adrian Rawcliffe and Chris Francis (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Chris Francis

SVP, Corporate Development, Head of Emerging Areas

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.1M99.6% planned, 0.4% to cover taxes

Kyle Moran

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.2M99% planned, 1% to cover taxes

Aik Tan

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.8MDisclosed plan

Christian Henry

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.4MDisclosed plan

Adrian Rawcliffe

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$807KDisclosed plan

All 11 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 12, 2026Adrian Rawcliffe sold 13K shares ($67K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Adrian Rawcliffe Director	12,700	$5.29	n/a	n/a	Aug 12, 2026	Aug 13, 2026

Outside holders, reported separately

RA CAPITAL MANAGEMENT, L.P. and GSK plc reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Wave Life Sciences, Inc. CEO selling stock?

Yes. Paul Bolno sold 10K shares ($141K) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Wave Life Sciences, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 98% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 2% were to cover taxes. A trading plan schedules sales in advance.

Are any Wave Life Sciences, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold11 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Chris Francis SVP, Corporate Development, Head of Emerging Areas	$7.1M 485K shares	Not confirmed share of stake is being verified. Why	99.6% under a disclosed plan, 0.4% to cover taxes
Kyle Moran Chief Financial Officer	$4.2M 264K shares	Not confirmed share of stake is being verified. Why	99% under a disclosed plan, 1% to cover taxes
Aik Tan Director	$1.8M 135K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Christian Henry Director	$1.4M 93K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Adrian Rawcliffe Director	$807K 71K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gregory Verdine Director	$269K 20K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Heidi Wagner Director	$231K 21K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Mark Corrigan Director	$217K 16K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Paul Bolno President and CEO, Director	$141K 10K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences	$43K 3.2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Ken Takanashi Director	$23K 3.9K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: GSK plc (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Ken Takanashi

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ken Takanashi are complete.

Director

n/a

−3.9K

n/a

Vesting, gifts, unvested awards and holding lines for Ken Takanashi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ken Takanashi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,230	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Chandra Vargeese

Chief Technology Officer, Head of Platform Discovery Sciences

n/a

−3.2K

n/a

Vesting, gifts, unvested awards and holding lines for Chandra Vargeese

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Chandra Vargeese are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
361,700	$3.87	Feb 5, 2034	$514K
224,000	$11.74	Feb 4, 2035	$0
273,750	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Gregory Verdine

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Gregory Verdine are complete.

Director

n/a

−20K

n/a

Vesting, gifts, unvested awards and holding lines for Gregory Verdine

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gregory Verdine are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,230	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Paul Bolno

President and CEO, Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Paul Bolno

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paul Bolno are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
47,778	$2.48	Mar 10, 2025	$134K
1,008,600	$3.87	Feb 5, 2034	$1.4M
1,000,000	$11.74	Feb 4, 2035	$0
1,000,000	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Kyle Moran

Chief Financial Officer

n/a

−264K

n/a

Vesting, gifts, unvested awards and holding lines for Kyle Moran

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kyle Moran are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$3.14	Jan 1, 2032	$161K
222,700	$4.75	Feb 17, 2033	$120K
371,500	$3.87	Feb 5, 2034	$528K
252,000	$11.74	Feb 4, 2035	$0
273,750	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Erik Ingelsson

Chief Scientific Officer

n/a

Vesting, gifts, unvested awards and holding lines for Erik Ingelsson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erik Ingelsson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
350,000	$5.85	May 8, 2034	$0
200,000	$11.74	Feb 4, 2035	$0
273,750	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Christopher Wright

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Wright

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Wright are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
300,000	$5.94	May 27, 2035	$0
273,750	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Heidi Wagner

Director

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Heidi Wagner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Heidi Wagner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,000	$5.97	Aug 16, 2026	$0
64,460	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Mark Corrigan

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Mark Corrigan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Corrigan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
64,460	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Aik Tan

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Aik Tan are complete.

Director

n/a

−135K

n/a

Vesting, gifts, unvested awards and holding lines for Aik Tan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Aik Tan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
152,400	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Christian Henry

Director

n/a

−93K

n/a

Vesting, gifts, unvested awards and holding lines for Christian Henry

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christian Henry are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,000	$3.50	Aug 15, 2027	$11K
32,230	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
15,000	$4.58	Aug 7, 2028	$11K
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Adrian Rawcliffe

Director

n/a

−71K

n/a

Vesting, gifts, unvested awards and holding lines for Adrian Rawcliffe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adrian Rawcliffe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,230	$5.37	Aug 12, 2029	$0
76,200	$8.11	Aug 11, 2030	$0
64,000	$3.75	Oct 5, 2036	$99K

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Chris Francis

SVP, Corporate Development, Head of Emerging Areas

n/a

−485K

n/a

Vesting, gifts, unvested awards and holding lines for Chris Francis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Chris Francis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
61,175	$4.75	Feb 17, 2033	$33K
143,200	$3.87	Feb 5, 2034	$203K
151,000	$11.74	Feb 4, 2035	$0
232,500	$12.75	Feb 5, 2036	$0

Estimate: options held × ($5.29 − strike price), using the most recent insider trade price on Form 4 (Aug 12, 2026), not a market close.

Holdings and share of stake for Wave Life Sciences, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$16.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $16.2M across 1,122,704 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $15.9M · 98%

The lighter segment is sales with no plan disclosed in the filing ($258K), including tax-related sales outside a plan.

Taxes

$284K of sales (1.8%) cite tax obligations in their footnotes, $26K of them also under a plan. Example: Aik Tan, Aug 11, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Chris Francis SVP, Corporate Development, Head of Emerging Areas	485K	$7.1M	99.6%	44%	Dec 8, 2025 to Feb 26, 2026
Kyle Moran Chief Financial Officer	264K	$4.2M	99%	26%	Dec 8, 2025 to Feb 9, 2026
Aik Tan Director	135K	$1.8M	100%	11%	Dec 8, 2025 to Aug 11, 2026
Christian Henry Director	93K	$1.4M	100%	8%	Dec 8, 2025 to Dec 8, 2025
Adrian Rawcliffe Director	71K	$807K	100%	5%	Nov 13, 2025 to Aug 12, 2026
Gregory Verdine Director	20K	$269K	100%	2%	Dec 8, 2025 to Dec 8, 2025
Heidi Wagner Director	21K	$231K	100%	1%	Dec 8, 2025 to Aug 11, 2026
Mark Corrigan Director	16K	$217K	100%	1%	Dec 8, 2025 to Dec 8, 2025
Paul Bolno President and CEO, Director	10K	$141K	0%	0.9%	Feb 9, 2026 to Feb 9, 2026
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences	3.2K	$43K	0%	0.3%	Feb 9, 2026 to Feb 9, 2026
Ken Takanashi Director	3.9K	$23K	100%	0.1%	Aug 11, 2026 to Aug 11, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$109K	$109K	$0	$0
Dec 2025	$15.0M	$15.0M	$0	$0
Jan 2026	$150K	$150K	$0	$0
Feb 2026	$758K	$500K	$258K	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$135K	$135K	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $16.2M sold, after almost none in the past 5 years. 11 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.12M	11	$16.2M
Oct 13, 2025 1 year earlier	910K	6	$10.8M
Oct 13, 2024 2 years earlier	81K	2	$530K
Oct 14, 2023 3 years earlier	97K	4	$417K
Oct 14, 2022 4 years earlier	157K	5	$313K
Oct 14, 2021 5 years earlier	22K	5	$229K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Wave Life Sciences, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology274 filings on record, 33 filed in the 12-month period, and how we read them

All 274 Forms 3, 4 and 5 on record for Wave Life Sciences, Inc. (SEC CIK 1631574), filed from Nov 10, 2015 to Oct 7, 2026; 33 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (10)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Michael Panzara	Jul 27, 2022	109,103 shares, last reported balance as of May 5, 2022
Amy Pott	Aug 20, 2020	No balance on record
David Gaiero	Mar 5, 2020	6,392 shares, last reported balance as of Feb 3, 2020
Koji Miura	Aug 16, 2019	No balance on record
Mark Baldry	Aug 7, 2019	39,000 shares, last reported balance as of Aug 5, 2019
Keith Regnante	Mar 11, 2019	29,186 shares, last reported balance as of Mar 7, 2019
Masaharu Tanaka	Sep 19, 2017	No balance on record
Masaharu Tanaka	Sep 19, 2017	2,774,118 shares, last reported balance as of Sep 18, 2017
Roberto Guerciolini	Dec 9, 2016	4,000 shares, last reported balance as of Dec 7, 2016
Takeshi Wada	Nov 14, 2016	100,635 shares, last reported balance as of Nov 10, 2015

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Wave Life Sciences, Inc. insiders sold $16.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Wave Life Sciences, Inc. CEO selling stock?

Why are Wave Life Sciences, Inc. insiders selling?

Are any Wave Life Sciences, Inc. insiders buying?

The evidence

Taxes

Sales by month